Ipsen’s Onivyde Hits Bullseye In Pivotal First-Line Pancreatic Cancer Trial
But Observers Waiting To Raise Sales Projections
The French firm’s Onivyde has succeeded as part of a combination regimen in chemotherapy-naïve pancreatic cancer patients, setting it up for a label expansion, but some experts are keen to see survival data in full before raising guidance.
